about
The current role of thiazolidinediones in diabetes management.Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?Antihypertensive drugs and glucose metabolismEffects of thyroid dysfunction on lipid profile.Are the pleiotropic effects of telmisartan clinically relevant?Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases.Acid-base and electrolyte disorders associated with the use of antidiabetic drugs.Proton pump inhibitors and statins: a possible interaction that favors low-density lipoprotein cholesterol reduction?Gitelman syndrome: an analysis of the underlying pathophysiologic mechanisms of acid-base and electrolyte abnormalities.Severe hyperkalemia following blood transfusions: Is there a link?Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective studyRosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose.Colesevelam plus rosuvastatin 5 mg/day versus rosuvastatin 10 mg/day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose.Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome.Effects of manidipine plus rosuvastatin versus olmesartan plus rosuvastatin on markers of insulin resistance in patients with impaired fasting glucose, hypertension, and mixed dyslipidemia.Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia.Reaching low density lipoprotein cholesterol targets.Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes.Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables.An insight into familial hypercholesterolemia in Greece: rationale and design of the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).L-Carnitine/Simvastatin Reduces Lipoprotein (a) Levels Compared with Simvastatin Monotherapy: A Randomized Double-Blind Placebo-Controlled Study.Antihypertensive drug therapy in patients with African ancestry.Combining rosuvastatin with angiotensin-receptor blockers of different PPARγ-activating capacity: effects on high-density lipoprotein subfractions and associated enzymes.Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH)Telmisartan: a multifaceted antihypertension drug.The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemiaHow safe is the use of thiazolidinediones in clinical practice?Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor-γ activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A₂Metformin and cancerStatin myopathy: navigating the mazeAn insight into familial hypercholesterolemia in Greece: rationale and design of the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH)Emerging Fixed-Dose Combination Treatments for Hyperlipidemia
P50
Q30250347-AB13F290-5026-4C80-9336-FFBC307D7270Q33776187-3C57F779-591D-4853-8C3F-930CC8371C45Q33948469-ADCAE650-A248-4ED7-AABD-7D824ADC5AA4Q34191474-7B3F5B3F-FCEA-48EB-B26A-677F75179163Q37581826-0C952A54-2FC9-499F-A337-D7441B4B31E5Q38208727-D994F05D-4CD7-4067-80FF-8B12960323FFQ38658251-ACA36A63-BF3C-4410-A463-4978C618FE1CQ39335694-220CE204-D481-4BF1-8A96-8021F9C9B439Q39458792-4875D2F6-627B-44D3-B728-944D910BE19FQ40805467-E51C9BC0-AD98-4E6D-A6AE-30093AC95372Q43095216-6EDF7EC9-E421-411B-9D6A-0751697936FCQ43289669-C01E07A0-44D8-4679-9974-D31FF56D3B6CQ43553765-73EC186A-8933-48AC-9504-EE4DE7DEA989Q46290681-229252E6-8D66-4404-845E-804DC097A74EQ46389068-0EDFE487-1189-41F4-BC01-2129E1ABCC00Q46514154-4711B12C-31FF-4AF3-89A4-9325ABD06A5EQ46953649-2BB32390-5ACF-4654-9127-B32F5C31430DQ47293312-EA972F31-F230-49CC-8ECF-91449E799252Q48209248-B4EC21F8-62A4-419E-9A03-C625AD3E9A48Q49573413-996022F9-5D99-461D-9A9D-694B05906091Q51287789-DA272F63-6E55-4C4F-8ABA-2C5E1D9BF687Q51744080-7185079E-56AC-486C-83D7-6D9550FCD55AQ54518829-FB9E1060-55DC-4BA2-A11E-EC1F527467E1Q57052358-456C0104-BF24-454E-987A-B16248CBAD93Q64939722-985FF1A6-1F07-453B-93CA-73D3E0801FE4Q83309710-46963869-2A7A-4977-9ED6-D8A9AD590A62Q83390234-F458DDDC-05D7-4DA6-B038-FCDECDEAB0D7Q83477641-8305892F-8B97-44E6-9AF2-5541DA616181Q86408684-4A100EB6-EAEB-413E-BA95-81EFBDF38F85Q88672652-4A42A374-274A-4636-98D2-ECF776F05287Q90847883-0E8370DF-038B-469E-A20C-D4CA170BFBC7Q92606662-1C262563-96A2-40FA-BD0D-19F5B378E0BE
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
C Rizos
@en
C Rizos
@nl
type
label
C Rizos
@en
C Rizos
@nl
prefLabel
C Rizos
@en
C Rizos
@nl
P31
P496
0000-0003-3495-9175